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ABSTRACT
Mast cell activation results in the immediate release of pro-
inflammatory mediators prestored in cytoplasmic granules, as well
as initiation of lipid mediator production and cytokine synthesis by
these resident tissue leukocytes. Allergen-induced mast cell acti-
vation is central to the pathogenesis of asthma and other allergic
diseases. Presently, most pharmacological agents for the treat-
ment of allergic disease target receptors for inflammatory me-
diators. Many of these mediators, such as histamine, are released
by mast cells. Targeting pathways that limit antigen-induced mast
cell activation may have greater therapeutic efficacy by inhibiting
the synthesis and release of many proinflammatory mediators
produced in the mast cell. In vitro studies using cultured human
and mouse mast cells, and studies of mice lacking A2B receptors,
suggest that adenosine receptors, specifically the Gs-coupled A2A
and A2B receptors, might provide such a target. Here, using a panel
of mice lacking various combinations of adenosine receptors, and
mast cells derived from these animals, we show that adenosine
receptor agonists provide an effective means of inhibition of mast
cell degranulation and induction of cytokine production both in
vitro and in vivo. We identify A2B as the primary receptor limiting
mast cell degranulation, whereas the combined activity of A2A and
A2B is required for the inhibition of cytokine synthesis.
Introduction
Mast cells play a central role in the pathogenesis of
allergic rhinitis, asthma, and anaphylaxis. Through de-
granulation and de novo production of lipid mediators, mast
cells are the major cell type responsible for the acute and
sometimes life-threatening manifestations of these allergic
disorders. Chronic mast cell activation is also believed to
contribute to the pathogenesis of asthma (Peachell, 2005;
Bradding et al., 2006; Yu et al., 2006). Mast cells are an
important source of Th2 cytokines, including interleukin
(IL)-4, IL-5, and IL-13 (Bradding et al., 1994; Brightling
et al., 2003; Galli et al., 2005). Infiltration of mast cells into
airway smooth muscle bundles has been reported in patients
with asthma, and this proximity may be important for the
development of airway hyper-responsiveness (Brightling
et al., 2002; James et al., 2012). In a murine model of
asthma, mast cells have been implicated in the development
of airway hyper-responsiveness, airway remodeling, and
IgE synthesis (Yu et al., 2006). Inhibiting mast cell
activation has therapeutic efficacy in asthmatic subjects,
further supporting the critical role for this immune cell in
disease pathogenesis (Rodrigo et al., 2011). However, drug
options for the inhibition of mast cell activation are limited.
Currently, two categories of medications are commercially
available to suppress the activity of mast cells: mast cell
membrane stabilizers, such as cromolyn and nedocromil
sodium, and the anti-IgE antibody omalizumab. Sodium
cromolyn at very high concentrations inhibits degranulation
of human lung mast cells by only 10%, suggesting that these
drugs may be inefficient at inhibiting the activity of mast cells
in vivo (Church and Hiroi, 1987). The clinical efficacy
of omalizumab has been demonstrated in several clinical
trials, and it is believed to be a more potent inhibitor of mast
cell activation than cromolyn (Boulet et al., 1997; Fahy et al.,
1997; Busse et al., 2001; Rodrigo et al., 2011). Although
omalizumab inhibits IgE/F«RI-mediated activation by anti-
gen, mast cells can also be activated through F«RI-
independent pathways. Chronic mast cell activation via these
alternative pathways may contribute to airway remodeling
(Peachell, 2005; Okayama et al., 2007; Carter and Bradding,
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2011). Therefore, additional means to inhibit mast cell
activity are of considerable interest.
Pharmacological agents with cAMP-elevating properties
have long been observed to inhibit mast cell function (Torphy,
1998). cAMP is a ubiquitous intracellular second messenger
that is produced from AMP after the activation of adenylyl
cyclase. We previously showed that cAMP can inhibit store-
operated calcium channels in mast cells through a protein
kinase A-dependent pathway, which subsequently limits
antigen-induced mast cell degranulation (Hua et al., 2007).
Different strategies can raise intracellular cAMP levels,
including activation of Gs-coupled receptors. For example,
b-adrenergic agonists can increase intracellular cAMP
through activation of Gs-coupled b-adrenergic receptors,
which in turn directly relaxes airway smooth muscle. Pre-
vious studies have shown that b-adrenergic agonists can also
increase cAMP in mast cells, and can inhibit mast cell
activation as a result (Church and Hiroi, 1987; Weston and
Peachell, 1998). However, because b-adrenergic receptors on
mast cells tend to internalize and desensitize once bound by
agonists, the capacity of b-adrenergic receptor agonists to
maintain high cAMP levels in mast cells is limited (Church
and Hiroi, 1987; Chong et al., 2003; Scola et al., 2004).
In addition to b-adrenergic receptors, mast cells express other
Gs-coupled receptors, including the A2 adenosine receptors A2A
and A2B (Marquardt et al., 1994; Zhong et al., 2003; Hua et al.,
2007). Activation of both A2A and A2B has been shown to
increase intracellular cAMP levels in many different cell types,
including mast cells (Pierce et al., 1992; Feoktistov and
Biaggioni, 1995; Olah, 1997; Fredholm et al., 2000). However,
whether activation of Gs-coupled adenosine receptors in mast
cells inhibits mast cell activation is still controversial, especially
in vivo. In vitro, adenosine has been shown to elicit both pro-
and anti-inflammatory effects on mast cells (Peachell et al.,
1991; Suzuki et al., 1998; Zhong et al., 2003; Hua et al., 2007);
however, in vivo studies have focused largely on adenosine-
induced mast cell activation (Tilley et al., 2000, 2003; Zhong
et al., 2001; Oldenburg and Mustafa, 2005; Hua et al., 2008).
Since adenosine is a potent anti-inflammatory mediator after
the initial phase of an immune response (Hershfield, 2005), we
hypothesized that adenosine might also inhibit mast cell
activation in vivo through activation of Gs-coupled A2A and/or
A2B receptors. In this study, we used genetic methods to
investigate the function of Gs-coupled adenosine receptors on
mast cells both in vivo and in vitro to evaluate their potential as
therapeutic targets for mast cell–mediated diseases.
Materials and Methods
Animals. All studies were conducted in accordance with the
Institutional Animal Care and Use Committee guidelines of the




mice were generated and genotyped by Southern blot analysis or
polymerase chain reaction as previously described (Ledent et al.,
1997; Hua et al., 2007; Salvatore et al., 2000). Each mouse line was
backcrossed 12 generations to the C57BL/6 genetic background. The





generated by intercrossing the corresponding double heterozygotes.
C57BL/6 wild-type control mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and bred in our animal facility. All
mice were housed in a pathogen-free facility with 12-hour day and
night switch. For all experiments, mice were greater than 8 weeks old
and wild-type and receptor-deficient animals were matched for age
and sex.
Bone Marrow-Derived Mast Cell Culture. Bone marrow-
derived mast cells (BMMCs) were isolated from the femurs of 8- to
12-week-old mice and grown in RPMI-1640 medium containing 10%
fetal calf serum, 20 ng/ml murine IL-3, and 20 ng/ml stem cell factor
as described previously (Salvatore et al., 2000). Cell purity was
determined by toluidine blue staining. Cell viability was determined
by trypan blue staining.
Hexosaminidase Release, Leukotriene B4, and IL-6
Measurements. Mast cell degranulation was determined by
b-hexosaminidase assay as described (Nguyen et al., 2002). For acute
treatment, 59-N-ethylcarboxamidoadenosine (NECA) (or adenosine)
was added 20minutes before the addition of the antigen dinitrophenyl-
human serum albumin (DNP-HSA). For chronic treatment, NECA was
added 20 hours before the antigen challenge. Hexosaminidase was
measured 30 minutes after stimulation by antigen. IL-6 and leukotri-
ene B4 (LTB4) concentrations in supernatants 6 hours after mast cell
activation were determined by enzyme-linked immunosorbent assay
(Nguyen et al., 2002; Hua et al., 2007). NECA treatment of these
experiments was the same as described in the degranulation assay.
Passive Systemic Anaphylaxis. Passive systemic anaphylaxis
(PSA) was performed as previously described (Hua et al., 2007). Mice
were injected intraperitoneally with NECA in dimethyl sulfoxide/
phosphate-buffered saline (DMSO/PBS) (10 mg/kg). They were then
given 2 mg of murine anti-DNP IgE monoclonal antibody (Sigma-
Aldrich, St. Louis,MO) via tail vein. A secondNECA treatment (10mg/kg)
was given 12 hours after IgE sensitization. Twenty-four hours after
the first NECA treatment, 100 mg of DNP-HSA (Sigma-Aldrich)
was injected intravenously to induce mast cell activation. Core body
temperature was recorded over time for the indicated period of time
using a rectal probe. Investigators were blinded to the treatment
given to each mouse during all experiments. The control groups were
injected intraperitoneally with vehicle only (DMSO/PBS) at each time
point. For histamine measurements, mice were sensitized with anti-
DNP IgE systemically as described above. They were then treated
with NECA by intraperitoneal injection (400 mg/kg). Twenty-four
hours later, these animals were injected with DNP-HSA via tail vein
to induce systemic anaphylaxis. Serum was collected immediately
after antigen injection and histamine levels were measured by
enzyme immunoassay (Cayman Chemical, Ann Arbor, MI).
Passive Cutaneous Anaphylaxis. In the passive cutaneous
anaphylaxis (PCA) model, mice were injected intraperitoneally with
NECA in DMSO/PBS (10 mg/kg). Their right ears were then injected
subcutaneously with 2 ng murine anti-DNP IgE monoclonal antibody
(Sigma-Aldrich) in 20 ml of PBS. The left ears were injected with 20 ml
of PBS as negative controls. A booster NECA treatment was given 12
hours after IgE sensitization. Twenty-four hours after IgE sensitiza-
tion, mice were injected with 0.2 ml 0.9% filtered Evans blue dye
containing 100 mg of DNP antigen through the tail vein. The mice
were euthanized 1 hour after DNP injection. Both the left and right
ears were collected and extravasated dye was extracted with
formamide. The optical density values at 610 nm of the pinna extracts
were measured.
Statistical Analysis. All data are presented as mean 6 S.E.M.
The paired Student’s t test was used for comparison before and after
treatment in the same subject. The two-tailed, unpaired Student’s t
test was used between different groups. Repeated-measures analysis
of variance was used to analyze differences between groups over time,
from the beginning of DNP-HSA injection through the response period.
Results
Activation of Gs-Coupled Adenosine Receptors Inhib-
its Antigen-InducedMast Cell Degranulation In Vivo. We
used PSA and PCA models to evaluate mast cell function in
vivo. Previous data indicate that murine mast cells, similar
to humans, express A2A, A2B, and A3 receptors, but not A1
receptors (Hua et al., 2007). Since adenosine can activate
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mast cells through A3 receptors in vivo (Salvatore et al.,
2000; Tilley et al., 2003), we used mice lacking A3 receptors
(A3
2/2) to investigate the effect of activation of the
Gs-coupled A2A and A2B receptors in PSA and PCA models.
For systemic anaphylaxis, A3
2/2 mice were given murine
anti-DNP IgE by intravenous injection. Mice were then
treated with NECA intraperitoneally. Twenty-four hours
later, mast cell degranulation was elicited in vivo by
intravenous administration of DNP-HSA. Body tempera-
ture drop was selected and recorded as a surrogate marker
to evaluate mast cell degranulation, as previously described
(Hua et al., 2007). Mice treated with NECA demonstrated
less drop in body temperature than mice treated with
vehicle (n5 7–10 per group; P , 0.05 by repeated-measures
analysis of variance), suggesting less mast cell degranulation in
the NECA pretreated group (Fig. 1A). Consistent with these
findings, PCA experiments also showed that NECA pretreat-
ment could limit antigen-induced mast cell degranulation in
vivo. As shown in Fig. 1B, mice treated with NECA prior to
antigen challenge demonstrated less plasma extravasation into
the ear (n5 7 per group; P, 0.01 by t test). To further establish
that our findings were reflective of mast cell degranulation, we
measured the levels of histamine in the serum of a separate
cohort of A3
2/2 mice during PSA. Mice pretreated with
NECA exhibited significantly lower histamine levels in their
serum during PSA compared with the vehicle-treated group
(P, 0.01; n5 10, 14, and 15 for the control, DNP, and DNP1
NECA groups, respectively). Collectively, these experiments
demonstrate that activation of Gs-coupled adenosine recep-
tors can inhibit antigen-induced activation of mast cells in
vivo.
Activation of Gs-Coupled Adenosine Receptors
Inhibits Antigen-Induced Mast Cell Degranulation In
Vitro. To further investigate the above in vivo findings, we
cultured BMMCs and tested the capacity of NECA to inhibit
antigen-induced degranulation. BMMCs from A3
2/2 mice
were cultured in vitro for 5 weeks in media containing murine
IL-3 and stem cell factor. The expression profile of adenosine
receptors on A3
2/2 BMMCs was measured using real-time
polymerase chain reaction. As expected, these cells only
expressed Gs-coupled adenosine receptors A2A and A2B, and
expression levels were similar to that of wild-type BMMCs
(unpublished data). After passive sensitization with murine
anti-DNP IgE (100 ng/ml per million cells for 12 hours), the
Fig. 1. Effect of NECA on antigen-inducedmast cell degranulation in vivo. (A) Passive systemic anaphylaxis (PSA). Mice were injected intraperitoneally
with NECA (10 mg/kg) (filled square, n = 7) or DMSO/PBS vehicle (open square, n = 10), and 2 mg murine anti-DNP IgE monoclonal antibody (mAb)
(Sigma-Aldrich) was administered via tail vein. A second NECA/vehicle treatment was given 12 hours after IgE sensitization. Twenty-four hours after
the first NECA treatment, 100 mg DNP-HSA antigen was injected intravenously. Data represent the mean body temperature6 S.E.M. every 10 minutes
postantigen administration. *P , 0.01 by repeated-measures analysis of variance. (B) Passive cutaneous anaphylaxis. Mice were injected
intraperitoneally with NECA or vehicle as described for PSA. Right ears were then injected subcutaneously with 2-ng murine anti-DNP IgE mAb in
20 ml of PBS. Left ears were injected with 20 ml of PBS. Twenty-four hours after IgE sensitization, mice were injected with 0.2 ml of 0.9% filtered Evans
blue dye containing 100 mg of DNP antigen by tail vein. One hour after DNP injection, ears were collected and extravasated dye was extracted with
formamide. Data represent the mean optical density values at 610 nm (right ear–left ear) of the pinna extracts 6 S.E.M. *P , 0.05 by Student’s t test
betweenNECA (filled bar, n = 7) versus vehicle (open bar, n = 7) groups. (C) Serum histamine levels during PSA.Mice were subjected to PSA as described
in (A), except 400 mg/kg NECA was used. Blood was obtained immediately after antigen (Ag) injection for measurement of serum histamine levels by
enzyme-linked immunosorbent assay. Data represent mean histamine level 6 S.E.M. **P , 0.001 by Student’s t test between NECA-treated mice (n =
14) versus vehicle-treated mice (n = 15). ##P , 0.001 between both NECA- and vehicle-treated mice versus naïve controls (n = 10).
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cultured A3
2/2 BMMCs were treated with adenosine for 20
min followed by antigen challenge. Mast cell degranulation
was quantitated by measuring hexosaminidase release. As
shown in Fig. 2A, acute activation of Gs-coupled adenosine
receptors on A3
2/2 BMMCs failed to modify antigen-induced
degranulation of BMMCs.
In our in vivo experiments, the inhibitory effects of NECA
on mast cell degranulation were observed approximately 20
hours after the initial treatment; we therefore increased the
incubation time prior to antigen challenge in the in vitro
experiments from 20 minutes to 20 hours. To see whether
increased time of incubation with NECA affected cell via-
bility, trypan blue staining was performed. No differences
were observed between NECA- and vehicle-treated cells
(unpublished data). Antigen-induced hexosaminidase release
in A3
2/2 BMMCs incubated without NECA was 14.9% 6 3%.
However, if cells were pretreated with NECA (20 mM) for 20
hours prior to the addition of antigen, the antigen-induced
hexosaminidase release from these cells was significantly
inhibited (5.8% 6 0.2%; n 5 3; P , 0.01) (Fig. 2B). Based on
these observations, we conclude that chronic but not acute
activation of Gs-coupled adenosine receptors can significantly
inhibit antigen-induced mast cell degranulation.
NECA Inhibits Mast Cell Degranulation through
Activation of the A2B Receptor. To determine whether
the inhibitory effects of NECA on antigen-induced degranu-
lation would still be detectable in cells expressing A3
receptors, we tested the effect of chronic NECA incubation
on degranulation of wild-type BMMCs. IgE-loaded BMMCs
were incubated with 20 mM NECA for 20 hours. Antigen-
induced mast cell degranulation was then evaluated by
measuring hexosaminidase release 30 minutes after stimula-
tion by DNP antigen. Similar to our findings in the A3
2/2
BMMCs, chronic treatment with NECA significantly inhi-
bited antigen-induced degranulation of wild-type mast cells
(13.8 6 3.1% in vehicle-treated cells versus 4.7 6 1.9% in
chronic NECA-treated cells; P , 0.001; n 5 4) (Fig. 3A). In
addition, the acute effect of NECA on antigen-induced mast
cell degranulation was also evaluated to ensure that func-
tional A3 receptors were expressed on these cells, as observed
in our previous studies (Salvatore et al., 2000; Tilley et al.,
2003). As expected, NECA added 15–20 minutes prior to
antigen challenge significantly increased antigen-induced
mast cell degranulation (P , 0.05, acute NECA versus
controls) (Fig. 3A). These data indicate that adenosine has
a biphasic effect on antigen-induced mast cell degranulation.
Acutely, adenosine acts as a proinflammatory mediator by
potentiating antigen-induced degranulation via A3 receptors;
chronically, adenosine inhibits antigen-induced mast cell
degranulation via Gs-coupled receptors regardless of the co-
expression of Gi/o-coupled A3 receptors.
To further substantiate this observation and to determine
the receptor subtype responsible for the chronic inhibitory
effect of NECA on degranulation, both A2A
2/2 and A2B
2/2
BMMCs were treated with NECA acutely and chronically
and antigen-induced hexosaminidase release was measured.
As shown in Fig. 3B, both the acute potentiation and chronic
inhibition of NECA were observed in A2A
2/2 BMMCs. This
finding not only further substantiates the biphasic effect of
adenosine on mast cell degranulation, but also indicates that
the inhibitory effect of NECA on degranulation is not me-
diated by A2A receptors. In BMMCs lacking A2B receptors, we
first observed an exaggerated mast cell degranulation in-
duced by antigen compared with the wild-type controls (26.8
6 2.4% versus 13.8 6 3.1%; P , 0.01 by the Student’s t test),
which is consistent with our previous observations (Hua et al.,
2007). Second, the acute potentiating effect of NECA was also
present in A2B
2/2BMMCs, as observed inwild-type andA2A
2/2
BMMCs (26.8 6 2.4% in DMSO vehicle-treated A2B
2/2 cells
versus 33.56 1.6% in NECA acutely treated A2B
2/2 cells; P,
0.05). However, when the A2B
2/2 BMMCs were chronically
treated with NECA, the inhibitory effect on degranulation
that was observed in wild-type, A2A
2/2, and A3
2/2 BMMCs
was abolished (Fig. 3C). These data indicate that the capa-
city of NECA to inhibit mast cell degranulation is mediated by
the A2B receptor.
We next conducted experiments to determine whether our
above-described in vitro observations implicating the A2B re-
ceptor were also present in vivo. Mice lacking the A3 receptor
(A3
2/2) and mice lacking both A2B and A3 receptors (A2B
2/2
A3
2/2) were sensitized with murine IgE mAb. They were
then given an intraperitoneal injection of NECA (400 mg/kg).
Fig. 2. Effect of acute versus chronic adenosine receptor stimulation on antigen-induced degranulation in vitro. (A) BMMCs from A32/2 mice were
sensitized with murine anti-DNP IgE antibody and incubated with adenosine (100 mM) or vehicle for 20 minutes. Mast cell degranulation was triggered
by addition of DNP-HSA antigen. Data represent the mean percent change in hexosaminidase release compared to vehicle-treated cells (controls)6 S.E.M.
P . 0.05 by the Student’s t test (n = 3 cell lines). (B) Anti-DNP IgE sensitized A3
2/2 BMMCs were treated with 20 mM NECA or vehicle for 20 hours and
hexosaminidasewasmeasured 30minutes after stimulationwithDNP-HSA antigen. **P, 0.01 by the Student’s t test betweenNECA versus vehicle (n = 3
cell lines per group).
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Antigen-induced mast cell degranulation was evaluated by
measuring serum histamine levels the next day immediately
after the intravenous administration of DNP antigen. As
shown in Fig. 4, treatment with DNP antigen resulted in
a marked increase in serum histamine level in A3
2/2 mice.
Antigen-induced histamine levels in the serum were signifi-
cantly attenuated in A3
2/2 mice, but not A2B
2/2A3
2/2 mice,
pretreated with NECA. These data demonstrate that A2B
receptors mediate the inhibitory effect of NECA in systemic
anaphylaxis.
A2A Receptors Do Not Influence Antigen-Induced
Mast Cell Degranulation. A2A receptors have long been
implicated as the major adenosine receptor subtype eliciting
inhibitory effects on leukocytes, including macrophages
and lymphocytes. Surprisingly, based on the above experi-
ments, activation of A2A receptors had no modulatory effect on
mast cell degranulation. To further examine the biologic role
of A2A receptors on mast cells, we investigated the impact of
genetic deletion of A2A receptors on antigen-induced mast cell
degranulation both in vitro and in vivo. BMMCs from wild-
type and A2A
2/2 mice were cultured for 5 weeks, and dose-
response studies of antigen-induced mast cell degranulation
were conducted. As shown in Fig. 5A, mast cells lacking A2A
receptors showed no significant differences in the magnitude
of antigen-induced hexosaminidase release compared with
wild-type mast cells. To further validate this in vitro ob-
servation, we conducted PSA and PCA experiments in mice
lacking A2A receptors. Ear plasma protein extravasation as
the result of PCA (Fig. 5B) and core temperature drop as
a result of PSA (Fig. 5C) were not different between A2A
2/2
and wild-type mice. Collectively, these data indicate that
activation of A2A receptors does not modify antigen-induced
mast cell degranulation.
Fig. 3. Effect of acute and chronic NECA on antigen-induced degranulation of wild-type, A2A2/2, and A2B2/2 mast cells. Cultured wild-type (A), A2A2/2
(B), and A2B
2/2 (C) mast cells were passively sensitized with murine IgE. The cells were then incubated with NECA acutely (20 minutes) or chronically
(20 h) prior to the addition of antigen. Controls were treated with aliquot vehicle. Hexosaminidase release was then measured to evaluate mast cell
degranulation. *P, 0.05 versus vehicle. Data are from three to four different sets of cells, and are presented as the mean percentage of hexosaminidase
release 6 S.E.M.
Fig. 4. Effect of NECA on antigen-induced mast cell degranulation in




mice were sensitized with murine IgE. These mice were then given NECA
intraperitoneally (400 mg/kg) as described previously in this study. Blood
was obtained immediately after antigen injection the next day for the
measurements of serum histamine levels by enzyme-linked immunosor-
bent assay. Controls include two groups of A3
2/2 mice treated with IgE/
vehicle/PBS and IgE/vehicle/ DNP. Data represent mean histamine level
6 S.E.M. (n = 5 in each group). *P , 0.05 by the Student’s t test between
NECA-treated A3
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NECA Inhibits Antigen-Induced IL-6 Synthesis in
BMMCs through A2A and A2B Receptors. In addition to
degranulation, activated mast cells can also synthesize pro-
inflammatory cytokines. To investigate the effect of activa-
tion of Gs-coupled adenosine receptors on antigen-induced
cytokine synthesis, we treated cultured BMMCs with NECA
chronically as described above, and the effects of this treat-
ment on antigen-induced IL-6 synthesis were analyzed.
Passively sensitized wild-type BMMCs were incubated with
20 mM NECA. Twenty hours later, cells were treated with
DNP for 6 hours and IL-6 levels in the supernatant were
measured. Chronic incubation with NECA did not cause
significant production of IL-6. In cells chronically pretreated
with NECA (20 hours), DNP antigen challenge could still
elicit synthesis of IL-6; however, the production of IL-6 in
these cells was significantly reduced (27% lower than the
vehicle/DNP group, n 5 14–15 per group; P , 0.0001) (Fig.
6A). These data indicate that chronic treatment with NECA
can inhibit antigen-induced cytokine synthesis in BMMCs. To
determine the adenosine receptor subtype(s) mediating this
inhibitory effect on cytokine synthesis, both A2A
2/2 and A2B
2/2
BMMCs were cultured and chronically treated with NECA
prior to DNP antigen challenge, and the capacity of NECA to
inhibit antigen-induced IL-6 synthesis was examined. Sur-
prisingly, the deletion of neither A2A nor A2B receptors
influenced the inhibitory effects of chronic NECA treatment
on IL-6 synthesis (Fig. 6B). These data further substantiate
the inhibitory effects of chronic NECA treatment on antigen-
induced cytokine synthesis in BMMCs, and also suggest that
the inhibition of IL-6 synthesis by NECA is not mediated by
either the A2A or A2B receptor. To investigate these obser-
vations further, we next cultured BMMCs lacking both A2A
and A2B receptors and tested the chronic inhibitory effect
of NECA on antigen-induced IL-6 synthesis. As shown in
Fig. 6C, the deletion of both A2A and A2B genes completely
abolished the chronic inhibitory effect of NECA on IL-6
synthesis in these mast cells. Collectively, these data indicate
that activation of Gs-coupled adenosine receptors can also
inhibit antigen-induced cytokine synthesis in BMMCs. In
contrast to mast cell degranulation in which the inhibitory
effect of chronic NECA was only mediated by the A2B re-
ceptor, NECA-induced inhibition on cytokine synthesis was
cooperatively mediated by both A2A and A2B adenosine
receptors.
Effect of NECA on Antigen-Induced Lipid Mediator
Release from BMMCs. In addition to degranulation and
cytokine synthesis, activated mast cells can also release ar-
achidonic acid–derived lipid mediators. To determine wheth-
er activation of Gs-coupled adenosine receptors could modify
antigen-induced lipid mediator release from mast cells, we
measured LTB4 levels in the supernatants of immunologically
activated mast cells that were incubated acutely (20 minutes)
or chronically (20 hours) with NECA prior to DNP antigen
challenge. Unlike the potentiating effect of acute NECA on
antigen-inducedmast cell degranulation, antigen-induced lipid
mediator release was not affected when DNP-stimulated cells
Fig. 5. In vivo and in vitro evaluation of antigen-induced degranulation in A2A2/2 mice. (A) Dose-response curve of hexosaminidase release with DNP-
HSA antigen in wild-type and A2A
2/2 BMMCs. P . 0.05 between wild-type and A2A
2/2 cells by repeated-measures analysis of variance. Data are from
BMMCs from three mice of each genotype, and are presented as mean percentage hexosaminidase release 6 S.E.M. (B) Passive cutaneous anaphylaxis
in wild-type and A2A
2/2mice. P. 0.05 by the Student’s t test (n = 5–6 per group). (C) Systemic anaphylaxis in wild-type and A2A
2/2mice. Data represent
mean temperature drop 20 minutes after DNP antigen 6 S.E.M. P . 0.05 by the Student’s t test (n = 5–7 per group).
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were pretreated acutely with NECA (Fig. 7A). Also in contrast
to the effects of chronic NECA on degranulation and cytokine
synthesis, DNP antigen–induced LTB4 production was no
different between mast cells incubated chronically (20 hours)
with vehicle orNECA. However, we did observe a 50% decrease
DNP-triggered LTB4 release by mast cells incubated for 20
hours with DMSO vehicle (approximately 100,000 pg/ml; Fig.
7A) compared with mast cells incubated for 20 minutes with
DMSO vehicle (approximately 200,000 pg/ml; Fig. 7B). Thus,
we cannot rule out the possibility that chronic NECA might
inhibit DNP-induced LTB4 release and that such an inhibitory
effect could not be observed due to potential effects of the
DMSO vehicle.
Discussion
Previous in vitro studies have shown biphasic effects of
adenosine on mast cell activity; however, the receptor
subtypes that mediate the inhibitory effects of adenosine are
still controversial (Peachell et al., 1991; Yip et al., 2009). Mast
cells express two distinct Gs-coupled adenosine receptors;
their biologic roles have not been comprehensively defined,
especially in vivo. Since activation of Gs-coupled adenosine
Fig. 6. Effect of NECA on antigen-induced IL-6 synthesis. Cultured wild-type (A), A2A2/2, A2B2/2 (B), and A2A2/2A2B2/2 (C) mast cells were passively
sensitized with murine IgE. The cells were then incubated with NECA (20 mM) chronically (20 hours) prior to the addition of antigen. Controls were
treated with aliquot vehicle. The IL-6 levels in the supernatants from these cells were then measured 6 hours after the addition of antigen. *P , 0.05
between NECA/DNP- and vehicle/DNP-treated groups by the Student’s t test. Data represent 15 different lines of cells in (A) and 3–4 different lines of
cells in both (B) and (C), and are presented as the mean percentage of the IL-6 levels in antigen (DNP)-treated cells 6 S.E.M.
Fig. 7. Effect of NECA on antigen-induced LTB4 synthesis by BMMCs. Mast cells were sensitized with murine anti-DNP IgE and incubated chronically
(20 hours) (A) or acutely (20minutes) (B) with 20 mMNECA, and LTB4 synthesis was induced with DNP-HSA antigen. LTB4 release in supernatants was
measured 6 hours later by enzyme-linked immunosorbent assay. Data for both (A) and (B) were from six different lines of cells, and are presented as
mean LTB4 levels 6 S.E.M.
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receptors increases intracellular cAMP, we hypothesized that
the inhibitory effects of adenosine on mast cells are mediated
by the Gs-coupled adenosine receptors. In this study, we used
both genetically modified animal models and mast cell
cultures to comprehensively investigate the role of Gs-coupled
adenosine receptors on mast cells both in vitro and in vivo.
First, our data demonstrate a potent inhibitory effect of the
nonhydrolyzable adenosine analog NECA on IgE-induced
mast cell degranulation; this inhibitory effect of NECA was
abolished by the genetic deletion of the A2B but not the A2A
receptor. Second, although A2A receptors also couple to Gs, we
were unable to demonstrate a role for this receptor subtype in
antigen-induced mast cell degranulation in vitro or in vivo.
Third, in addition to mast cell degranulation, activation of Gs-
coupled adenosine receptors significantly inhibited antigen-
induced synthesis of IL-6 in mast cells; this inhibitory effect
wasmediated by both A2A and A2B receptors. Last, our in vitro
studies revealed a time-dependent biphasic effect of adeno-
sine on mast cell activation. Acutely, adenosine enhances
mast cell degranulation but chronically, it limits mast cell
activation.
Adenosine levels are elevated in bronchoalveolar lavage
fluid from asthmatic subjects (Driver et al., 1993). Adenosine
inhalation causes immediate bronchoconstriction in asth-
matic subjects but not in normal subjects, an effect that can be
inhibited by antagonizing adenosine-induced mast cell acti-
vation (Cushley et al., 1983; Phillips et al., 1989). Based on
these observations, it has been posited that adenosine
activates mast cells and contributes to asthma pathogenesis,
and that antagonizing the proinflammatory adenosine re-
ceptor subtype may benefit asthmatic subjects (Polosa and
Blackburn, 2009). The adenosine receptor subtypes that
potentially mediate these proinflammatory effects on mast
cells include A1, A2B, and A3 receptors as suggested by
previous studies (Ali et al., 1994; Feoktistov and Biaggioni,
1995; Salvatore et al., 2000; Feoktistov et al., 2001, 2003;
Tilley et al., 2003; Zhong et al., 2004; Chen et al., 2006; Young
et al., 2006; Yip et al., 2009; Hua et al., 2011). However,
clinical trials have failed to demonstrate the efficacy of
antagonizing these three adenosine receptors in asthmatic
subjects, suggesting that the biologic roles of adenosine in
asthmatic lungs needs to be re-evaluated (Ball et al., 2003;
Pascoe, 2007).
In this study, we observed a time-dependent, biphasic effect
of adenosine on mast cell activation. Acutely, adenosine
enhanced mast cell degranulation; chronically, adenosine
limited mast cell activation. Adenosine is produced by the
metabolism of ATP released by cells during hypoxia and other
pathophysiological conditions resulting in cellular stress. ATP
and its metabolites adenosine and uric acid are major danger-
associated molecular patterns, the biologic role of which is to
help maintain and restore in vivo homeostasis after cellular
stress (Willart and Lambrecht, 2009). The time-dependent,
biphasic effects that we and others have observed with aden-
osine may confer this molecule a unique role in maintaining
homeostasis after tissue injury. Acutely, adenosine functions
as a danger-associated molecular pattern, signaling the in
vivo “alarm system” by upregulating the inflammatory re-
sponse. Chronically, adenosine through preconditioning and
inhibition of the inflammatory response, may act to prevent
excessive tissue injury and to help eventually restore
homeostasis (Fredholm, 2007). Human studies from our
center have shown increased adenosine levels in the induced
sputum from asthmatic subjects with mild, moderate, and
severe persistent asthma. These subjects were stable and
were not in the midst of an asthma exacerbation, suggesting
that adenosine levels are chronically elevated in the lungs of
asthmatic subjects, particularly those with more severe
disease. Therefore, in combination with previous studies, this
report suggests that the chronically accumulated adenosine in
asthmatic lungs may be anti-inflammatory rather than
proinflammatory.
Our observations of the inhibitory effects of adenosine on
antigen-induced mast cell degranulation in vitro are consis-
tent with several previous reports on human lung fragments,
dispersed human lung mast cells and human umbilical cord
blood–derived mast cells (HUCBMCs) (Hughes et al., 1984;
Peachell et al., 1988, 1991; Suzuki et al., 1998). At least three
independent studies have shown that adenosine can inhibit
antigen-induced histamine release from human lung frag-
ments and dispersed human lung mast cells (Hughes et al.,
1984; Peachell et al., 1988, 1991). Although these investi-
gators showed that the inhibitory effects of adenosine could be
blocked by inhibiting cell-surface adenosine receptors, the
tools to identify and isolate specific receptors were not
available at the time of these investigations. Peachell et al.
(1988) found that low concentrations of adenosine potentiated
(,1 mM), and high concentrations inhibited (100 mM),
antigen-induced degranulation of human lung mast cells.
Given the low affinity of the A2B receptor for adenosine, these
observations suggest that the A2B receptor might mediate
these inhibitory effects on human lung mast cells. Yip et al.
(2011) also observed a similar biphasic effect of adenosine on
anti-IgE–induced human mast cell activation. By using phar-
macological antagonism, this group reported that the poten-
tiating and inhibitory effect of adenosine was mediated by A1
and A2B receptors, respectively. In contrast, using in vitro
cultured HUCBMCs, Suzuki et al. (1998) found that IgE
crosslink-induced mast cell degranulation could be inhibited
by the A2A receptor agonist 2-p-(2-Carboxyethyl)phene-
thylamino-59-N-ethylcarboxamidoadenosine (CGS-21680),
and that this inhibition could be effectively prevented by
4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol (ZM241385), a potent A2A receptor
antagonist, suggesting a role for the A2A receptor in
adenosine-mediated inhibition of degranulation. In addition,
Rork et al. (2008) found that activation of A2A receptors can
limit mast cell degranulation in the murine heart, decreasing
reperfusion injury. A study using cheek pouch of the golden
hamster also revealed an inhibitory effect of activation of A2A
receptors on inosine-induced periarteriolar mast cell de-
granulation (Fenster et al., 2000). In contrast, our mouse
studies both in vitro and in vivo do not support a role for A2A
receptors in antigen-induced mast cell degranulation.
Mast cells are a highly heterogeneous cell type. They
originate in bone marrow but mature in peripheral organs
where they acquire different phenotypic properties after
differentiation in the local milieu, which may differ between
tissues. It is possible that the environment in which the mast
cell resides influences adenosine receptor expression and
function, accounting for the differences in receptor effects
observed between these studies. Although several studies
have suggested that A2A receptors mediate anti-inflammatory
effects (Antonioli et al., 2010; Fenster et al., 2000; Harada
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et al., 2000; Kreckler et al., 2006; Rork et al., 2008; Trevethick
et al., 2008), a clinical trial failed to demonstrate efficacy of
an A2A agonist in attenuating allergen-induced early and
late reactions, sputum total cell counts and EG21 cell
numbers, eosinophil cationic protein levels, or inflammatory
cytokine production in asthmatic subjects (Luijk et al.,
2008).
Investigations on the biologic role of the Gs-coupled A2B
receptor have yielded conflicting results. Studies on HMC-1
cells have revealed a proinflammatory role for A2B receptors
(Feoktistov and Biaggioni, 1995; Meade et al., 2002; Ryzhov
et al., 2004, 2006). Similarly, our study using HUCBMCs
showed that IgE-crosslinking-induced mast cell activation
was augmented by A2B receptor activation, further suggesting
a proinflammatory role for the A2B receptor on mast cells in
vitro (Hua et al., 2011). However, these in vitro observations
have not held up in vivo. For example, in a placebo-controlled,
double-blinded, randomized, two-way crossover phase Ib
clinical trial, the compound QAF805, which antagonizes both
A2B and A3 receptors, failed to demonstrate efficacy in
attenuating AMP-induced bronchial hyper-responsiveness in
asthmatic subjects (Pascoe, 2007).
Previous studies by our group and others have ascribed an
anti-inflammatory phenotype to the A2B receptor. We pre-
viously reported that murine mast cells lacking A2B receptors
exhibited an exaggerated response to antigen (Hua et al.,
2007), suggesting an anti-inflammatory role for A2B recep-
tors in mice. In addition, activation of A2B receptors have
been reported to reduce the severity of inflammation in
lipopolysaccharide-induced murine macrophage activation,
murine sepsis, and a mouse model of ventilation-induced lung
injury (Kreckler et al., 2006; Yang et al., 2006; Eckle et al.,
2008; Csóka et al., 2010). In this study, we also found that the
chronic inhibitory effect of adenosine on mast cell activation
was abolished by genetic deletion of the A2B receptors both in
vivo and in vitro, further supporting an anti-inflammatory
role for A2B receptors on mast cells.
In addition to inhibiting degranulation, we also found that
chronic stimulation of Gs-coupled adenosine receptors by
NECA could inhibit antigen-induced cytokine synthesis. Sur-
prisingly, we were unable to attribute this inhibition to
a single adenosine receptor subtype. Mast cells lacking either
A2A or A2B receptors responded similarly to wild-type cells,
suggesting that the presence of an A2A-Gs or A2B-Gs signal
was sufficient to mediate the inhibitory effects of NECA.
Interestingly, activation of both Gs-coupled receptors on wild-
type mast cells was no more effective than activation of either
receptor in isolation on mast cells from A2A- or A2B-deficient
mice. When mast cells devoid of both Gs-coupled receptors
were examined, the inhibitory effect of NECA on antigen-
induced IL-6 synthesis was abolished.
The capacity of adenosine to potently regulate inflamma-
tion has made the G-protein– coupled adenosine receptors
attractive pharmacological targets. Our findings of an in-
hibitory role for the A2B receptor, both constitutively (Hua
et al., 2007) and when chronically stimulated, may have
implications for A2B antagonists under development for the
treatment of asthma. A more detailed understanding of the
mechanisms by which adenosine regulates the immune
response in a biphasic fashion will be critical to the successful
introduction of adenosine receptor ligands for the treatment
of asthma and other inflammatory diseases.
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